Thermo Fisher, A54401, TaqPath™ Seq HIV-1 Genotyping Kit

Quantity: 48 tests
Unit Size: Each
• A CE-IVD kit designed to genotype the protease, reverse transcriptase (RT), and integrase (IN) regions of the HIV-1 pol gene
• The genotyping result encompasses codons 6-99 in the PR region, codons 1-251 in the RT region, and codons 1-288 of the IN region of the gene
• HIV-1 genomic mutations in these regions confer resistance to anti-retroviral drugs that act through the inhibition of the protease and reverse transcriptase
• Enables reliable genotyping of the genetically diverse HIV-1 virus to investigate drug resistance mutations (DRMs) to protease inhibitors (PI), nucleoside reverse-transcriptase inhibitors (NRTI), non-nucleoside reverse-transcriptase inhibitors (NNRTI), and integrase inhibitors (INSTI) from HIV-1 RNA extracted from EDTA plasma and dried blood spot samples
• The kit contains ready-to-use master mix, enzyme, and positive and negative controls to cover the three phases of the workflow: RT-PCR, nested PCR, and bidirectional cycle sequencing steps to process 48 test samples
• Delivers gold-standard Sanger sequencing results for use in the identification of drug resistant mutations from the diverse and rapidly evolving HIV-1 virusFeatures and benefits of the TaqPath Seq HIV-1 Genotyping Assay:
• Cost-effective, CE-IVDD compliant test developed in collaboration with the U.S. CDC
• Designed for a wide range of group-M subtypes, addressing strains found predominantly in the regions with the greatest need
• From sample to result in ∼14 hours
• Covers the protease, reverse transcriptase and integrase regions of the pol gene
• Scalable workflow
• Pre-mixed reagents to minimize pipetting steps
• Easy-to-read sequencing results
• First regulated Sanger sequencing product to address all three regions of the pol gene